Form 4: UroGen Pharma CFO Sells Shares
Insider Transaction (Form 4)
Chris Degnan, Chief Financial Officer of UroGen Pharma Ltd., sold 2,202 shares of common stock on October 8, 2026 for $36.69 per share.
Summary
- Option exercise/conversion: acquired 4,483 Ordinary Shares on October 8, 2026; holds 6,763 after (Direct).
- Open-market sale: disposed of 2,202 Ordinary Shares at $36.69 ($80,791) on October 8, 2026; holds 4,561 after (Direct).
- Option exercise/conversion: disposed of 4,483 Restricted Stock Units on October 8, 2026; holds 4,484 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $80,791 of stock on the open market.
Insider Transactions
Chris Degnan — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-08 | Option exercise/conversion | Ordinary Shares | 4,483 | — | — | 6,763 |
| 2026-10-08 | Open-market sale | Ordinary Shares | 2,202 | $37 | $80.8K | 4,561 |
| 2026-10-08 | Option exercise/conversion | Restricted Stock Units | 4,483 | — | — | 4,484 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-08 | Option exercise/conversion (4,483 shares) |
| 2026-10-08 | Open-market sale (2,202 shares) |
| 2026-10-08 | Option exercise/conversion (4,483 shares) |
Keywords
insider transaction, Form 4, URGN, UroGen Pharma Ltd., bearish, Chris Degnan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.